Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + albumin-paclitaxel + platinum for first-line ES-SCLC (Phase II)
ChiCTR2300077236Phase 2Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Nov 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in small cell lung cancer (SCLC), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Half-year progression-free survival rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300077236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077236.